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Abstract.  Primary monolayers of rabbit articular chon- 
drocytes synthesize high levels of type II collagen 
and proteoglycan.  This capacity was used as a marker 
for the expression of the differentiated phenotype. 
Such cells were treated with  1 Bg/ml retinoic acid 
(RA) for  10 d to produce a modulated collagen pheno- 
type devoid of type II and consisting of predominantly 
type I trimer and type III collagen.  After transfer to 
secondary culture in the presence of RA, the stability 
of the RA-modulated phenotype was investigated by 
culture in the absence of RA. Little reexpression of 
type II collagen synthesis occurred in this period un- 
less cultures were treated with 3  x  10  -6 M dihydro- 
cytochalasin B to modify microfilament structures. 
Reexpression of the differentiated phenotype began be- 
tween days 6-8 and was essentially complete by day 
14. Substantial reexpression occurred by day 8 without 
a detectable increase in cell rounding.  Colony forma- 
tion,  characteristic of primary chondrocytes, was infre- 
quent even after reexpression was complete. These 
data suggest that the integrity of microfilament cyto- 
skeletal structures can be a  source of regulatory sig- 
nals that mechanistically appear to be more proximal 
to phenotypic change than the overt changes in cell 
shape that accompany reexpression of subculture- 
modulated chondrocytes in agarose culture (Benya, 
P. D., and J.  D.  Shaffer,  1982.  Cell.  30:215-224). 
C 
HONDROCYTE differentiated  functions  include  the 
synthesis,  deposition, and maintenance  of an extra- 
cellular matrix composed of cartilage-specific  colla- 
gens and proteoglycans.  Analysis of the transitions in synthe- 
sis  of these macromolecules to  other  genetically  distinct 
collagens  and proteoglycans  has  demonstrated  the pheno- 
typic flexibility of chondrocytes in culture (7).  Modulation 
of the differentiated phenotype occurs after subculture (13), 
growth to senescence (32), and treatment  with retinoic acid 
(RA)  1 (8,  51), 5-bromo-2'-deoxyuridine (BrdU)  (33,  42), 
PMA (18), and temperature-sensitive  virus (1, 3). In several 
of these cases modulation can be reversed (1, 10, t8). Using 
rabbit articular chondrocytes,  we have previously demon- 
strated  essentially complete reexpression of the differenti- 
ated collagen  phenotype when subculture-modulated  cells 
respond to an overt change in shape,  from spread/attached 
to spherical,  that accompanies the transition from monolayer 
to agarose gel culture (10). Thus, chondrocytes (10, 52), their 
mesenchymal precursors  (41), and other  shape-responsive 
expression systems, i.e., preadipocytes (46),  synovial fibro- 
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blasts (2, 48), and mammary epithelial cells (21), may share 
similar  regulatory mechanisms. 
To investigate  the possible role of modifications  in mi- 
crofilament  architecture  as a mediator  in shape-dependent 
reexpression  of chondrocytes,  we have tried to separate these 
events and identify microfilament modification as an indepen- 
dent signal for reexpression.  Dihydrocytochalasin B (DHCB) 
was used as a specific perturbant of microfilament organiza- 
tion (4) at a dose previously determined to minimize  cell 
rounding while permitting reexpression of subculture-modu- 
lated chondrocytes (11). RA-modulated  chondrocytes were 
used as an experimental system because they produce no type 
II collagen, exhibit a  different  modulated phenotype than 
subculture-modulated  ceils, and are flattened and tightly ad- 
herent (8). 
We report here that  RA-modulated  chondrocytes exhibit 
nearly complete reexpression of the differentiated  collagen 
phenotype only after removal of RA and culture in the pres- 
ence of DHCB for 14 d. During the first 8 d of microfilament 
modification (14) ~50% reexpression  occurs without appar- 
ent cell rounding. This suggests that microfilament modifica- 
tion can be a sufficient signal for phenotypic change and may 
mediate the effects of alterations  in cell shape. In monolayer 
culture, however, this signal does not induce type II collagen 
synthesis in all cells as determined by collagen-type specific 
immunofluorescence.  We also report that reexpression in this 
system requires the presence of 10% FBS; 1 or 2% serum 
will not support this transition. 
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Cell Culture 
Chondrocyte monolayer cultures were established (12, 13) from the articular 
cartilage of the humeral head of 8-wk-old New Zealand white rabbits. Cells 
were plated at 6.0  x  104 cells/cm  2, The growth medium was DME, high- 
glucose modification (Gibco, Santa Clara, CA), containing 10% FBS (Hy- 
Clone Laboratories, Inc., Logan, UT) and 50 ~g/ml gentamycin. Treatment 
with RA was initiated on the fourth day of culture.  All-trans RA (Sigma 
Chemical Co., St. Louis, MO) was dissolved in 95% ethanol at 1.0 mg/ml 
and held as a stock solution at -20~  in the dark. This solution was diluted 
with growth medium each day before the cultures were fed. Control and 
treated cultures were fed every other day after the fourth day. After 10 d of 
RA treatment, RA-modulated cells were transferred to secondary culture 
and  plated  in  the presence of RA  at  2.8  x  104  cells per cm  2.  When 
confluent cultures were obtained after 4 d, RA was removed to begin the 
reexpression period. During this time cultures were maintained in 10%, or 
1%  or 2%  serum,  in the absence or presence of 3  ￿  10  -6 M  DHCB 
(Sigma Chemical Co.). Cultures maintained in 1% serum were treated with 
10% serum for 1 d before the labeling period to equilibrate the levels of pro- 
tein synthesis with those in cultures maintained in  10% serum. 
DNA and Proteoglycan Synthesis 
Proteoglycan synthesis and  DNA content were measured in aliquots of 
pronase digests of combined medium and cell layers as cetyltrimethylam- 
monium  bromide-precipitable  35SO4 and  diaminobenzoic  acid-derived 
DNA fluorescence, respectively (8L 
Collagen Synthesis 
Duplicate cultures were  labeled for 24  h  with  L-[5-3H]-proline  (20-50 
Ci/mmol, 50 p,  Ci/ml; Amersham Corp., Arlington Heights, IL) in growth 
medium supplemented with I~-amino-proprionitrile  (62.5 p.g/ml) and ascor- 
bate (50 I.tg/ml). Whole cultures (medium and cell layer) were stored frozen, 
thawed to 4~  adjusted to 0.5 M acetic acid and treated with I mg/ml pepsin 
(PM grade; Cooper Biomedical, Malvern, PA) for 24 h at 4~  Tris base 
was added to 0.1 M and the pH was adjusted with NaOH to 8.0 to inactivate 
the pepsin. After adjustment to 200 p.g/mt carrier collagen, 0.5 M  NaCI, 
and 2 M urea, samples were extracted for 1 h at 4~  removed from the 
culture flasks,  and dialyzed against 1 M NaCI, 50 mM Tris, pH 7.5 to re- 
move unincorporated label. Cellular debris was removed by centrifugation 
and the supernatants were dialyzed overnight against 0.4 M NaC1, 50 mM 
Tris, pH 7.5, before collagen precipitation by addition of an equal volume 
of 20% polyethylene glycol 8000 (J. T. Baker) and overnight incubation at 
4~  (modified from reference 40). Collagen precipitates were dissolved in 
0.2 M NaCI, 50 mM Tris-HC1,  pH 7.5, and dialyzed against 0.5 M acetic 
acid before counting to determine total collagen synthesis and analysis by 
SDS-PAGE. 
SDS-PAGE 
We fractionated lyophilized samples of  purified radioactive collagen in com- 
posite linear-gradient acrylamide slab gels using the SDS sample and gel 
buffers described by Laemmli (31). Composite gels were made from a stock 
solution containing 30% acrylamide, 0.8 % bis, by combining 1 vol of 20% 
acrylamide in a closed mixing outlet chamber,  1.5 vol of 3% acrylamide 
in an open supply chamber, and using the entire contents of both chambers 
for each slab gel. Samples were electropboresed, fixed in 20% TCA, and 
processed for fluorography as previously described (9). 
2-D CNBr Peptide Mapping 
Purified collagen was precipitated from 0.5 M acetic acid with 2.5 M NaCI 
to remove polyethylene glycol and dialyzed against 0.5 M acetic acid before 
lyophilization. Samples were suspended in 500  ~1 of 25%  13-mercapto- 
ethanol, 0.2 M ammonium bicarbonate, pH 7.8, adjusted with acetic acid, 
and incubated overnight at 60~  (5). This procedure completely reduced 
the oxidized methionines caused by contaminants in the polyethylene gly- 
col, as verified by the expected low level of peptides incompletely cleaved 
by CNBr (see Fig. 5). CNBr cleavage (9) was followed by two-dimensional 
(2-D) CNBr peptide mapping which consisted of nonequilibrium pH gra- 
dient electrophoresis in the first dimension and  SDS-PAGE using Tris- 
borate buffers in the second dimension (6). Peptide spots in 2-D maps were 
quamitated in the linear range as total integrated optical density using the 
Visage machine vision image analyzer (Bio Image Corp., Ann Arbor, MI), 
which has been previously described (37) and utilized for 2-D mapping 
analysis (43).  The resultant data were used to calculate the synthesis per 
microgram DNA of collagen types I, II, and III as described in the legend 
to Fig. 5. 
Collagen Immunofluorescence 
Cells were cultured in chamber slides (14), incubated at 37~  with 1 I.tM 
monensin (Sigma Chemical Co.) for 6  h to enhance the intracellular ac- 
cumulation of collagen (36), washed with PBS, and fixed in 3.7 % parafor- 
maldehyde in PBS at 37~  for 10 min. After methanol treatment at -20~ 
for 6 min and air drying, slides were incubated with PBS before treatment 
with hyaluronidase (Cooper Biomedical) 1,000 U/mg, l mg/ml in PBS, for 
40 rain at 37~  Type I1 collagen-specific  mouse mAb (clone C2) was gener- 
ously provided by K. Rubin and has been previously characterized (25). 
Ceils were incubated for 1 h at 37~  with ascites fluid diluted 1:50 with 1 
mg/ml BSA in PBS. This was followed by washing, incubation with bio- 
tinylated second antibody, and detection with Texas  Red-labeled strep- 
tavidin as described (14). 
Results 
Morphology 
After 4  d  of secondary culture  in  the presence  of RA, 
confluent RA-modulated chondrocytes were evaluated for 
their capacity to reexpress the differentiated phenotype dur- 
ing a 21-d reexpression period in the absence of  RA. Cultures 
were maintained in medium that contained 10 % FBS without 
or with DHCB. The dose of DHCB, 3  ￿  10  -6 M, was cho- 
sen because it maximized reexpression and minimized cell 
rounding in subculture-modulated chondrocytes (11). Repre- 
sentative  phase  contrast  micrographs  of  RA-modulated 
chondrocytes during the reexpression period (Fig. 1) demon- 
strate that DHCB did not alter the degree of  cellular rounding 
during the first 8 d of exposure and only slightly modulated 
the shape of the cellular footprint to a more elongate form 
(Fig.  1, a  and b), less fibroblastic than that of subculture- 
modulated chondroc~tes (13). Substantial reexpression of  the 
collagen phenotype occurred in this 8-d period (see next sec- 
tion). The morphology of nearly all DHCB-treated cells was 
maintained at 14 d when collagen phenotypic reexpression 
was essentially complete. Colony formation, characteristic 
of differentiated primary chondrocyte cultures, was only oc- 
casionally observed at this time (Fig.  1 c), but increased 
slightly by 21 d of treatment (Fig.  I d). 
Proteoglycan and Collagen Synthesis 
During the reexpression period these confluent cultures ex- 
hibited only small changes in DNA content (Fig. 2).  The 
gradual increase observed in untreated cultures was arrested 
in DHCB-treated cultures after 8  d.  The maintenance of 
DNA content over the extended exposure to DHCB verifies 
the utility of the dose and supports the continued adherence 
of spread cells presented in Fig.  1. 
At the beginning of the reexpression period proteoglycan 
synthesis per microgram DNA by cells in RA remained at 
the same low level as RA-treated cells in primary culture 
(Fig. 2 and unpublished data). The eightfold greater synthe- 
sis observed in primary control cells (8)  was reduced to 
threefold in secondary control cells (Fig. 2 and unpublished 
data) due to the decline in proteoglycan synthesis that accom- 
panies subculture-dependent modulation of the chondrocyte 
The Journal  of Cell Biology,  Volume 106, 1988  162 Figure 1. Phase contrast micrographs of RA-modulated chondrocytes in secondary culture at various times after removal of RA. After 8 d 
without DHCB (a); paired 8-d culture treated with 3  ￿  10  -6 M DHCB (b); after 14 (c) and 21 (d) days of DHCB treatment. The field 
in (d) was not representative but was chosen to demonstrate colony formation, which was infrequent. Bar, 100 ltm. 
phenotype (10). After removal of RA,  DHCB-treated cells 
exhibited a  steady increase in proteoglycan synthesis, first 
noticeable after 4 d and reaching a maximum after 14 d of 
2.5-fold above that of cells cultured in the absence of DHCB. 
The final level was above that exhibited by control chondro- 
cytes at the beginning (Fig. 2) and the end (unpublished data) 
of the reexpression period. This suggests a quantitative re- 
turn of this characteristic of differentiated chondrocytes. 
Collagen synthesis per microgram DNA in RA-modulated 
ceils at the beginning of the reexpression period was only 
slightly less than that in untreated control cells (Fig. 3). The 
eightfold lower rate observed in such cells in primary culture 
(8) was not retained due to the subculture-dependent reduc- 
tion in type II collagen synthesis by control chondrocytes (13) 
and the fact that secondary RA-modulated chondrocytes pro- 
duce  collagen  approximately  fivefold faster than  primary 
chondrocytes treated with RA for 10 d  (unpublished data). 
The  stimulated  synthesis  in  RA-treated  secondary  cells 
reflects  the  recovery of enhanced  type  III  synthesis  (8) 
producing the high type III:I-trimer ratios seen in Figs. 4 and 
6 at the beginning of the reexpression period. When RA was 
removed and cells were cultured without DHCB, collagen 
synthesis  was  maintained  until  day  4  and  then  declined, 
reaching a minimum 10-fold less than the initial value at 21 d. 
DHCB-treated cells exhibited a marked decrease in synthesis 
after 2 and 4 d and then nearly regained the initial rate by 
14  d.  Collagen  synthesis  in  DHCB-treated  cultures  was 
greater than in untreated cultures beginning on day 6  and 
reached a maximum of eightfold greater than such cultures 
by 21  d.  After  14 d  of reexpression,  synthesis in  DHCB- 
treated cultures  was  slightly less  than  in  control cultures 
(never treated wth RA) at the beginning of reexpression (Fig. 
3) but equal to or greater than control cultures at 14 d (two 
separate studies). 
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Figure 2. DNA content and proteoglycan synthesis during the 21-d 
reexpression period that followed removal of RA. Synthesis/DNA 
content of RA-modulated cells in the presence of RA at the begin- 
ning of the reexpression period (diamond); of secondary control 
cells never treated with RA (square); and of RA-modulated cells 
cultured in the absence of RA without (triangles) and with (circles) 
DHCB treatment. Data represent the average of duplicate cultures. 
The mean of the ranges for the DNA data is +7 %, and for the pro- 
teoglycan data,  +18%. 
Collagen Phenotype 
A proportional analysis of the change in collagen phenotype 
during the RA-free reexpression period is presented in Fig. 
4  based  on  separation  of intact collagen chains  by SDS- 
PAGE. Variation in the ratio of type III collagen to al-chains 
occurred during the first 6 d in both untreated and DHCB- 
treated cultures. The initiation of type II synthesis was first 
detected on day 8 in DHCB-treated cultures. This is most 
clearly  seen  in  the  underexposed inset,  where  the  more 
abundant al(II)-chains migrate slightly faster than the al(I)- 
chains of  type I trimer. At later times the abundance of al(II)- 
chains obscures this separation. By 21 d DHCB-treated cul- 
tures exhibited a phenotype more differentiated than control 
secondary chondrocytes as  indicated by the complete ab- 
sence of a2(I) chains. 
To provide a  detailed quantitative time-course for reex- 
pression based on the synthesis per microgram DNA of col- 
lagen types I trimer, II, and III, and to significantly enhance 
the reliability and detection sensitivity for the initiation of 
type II synthesis, we cleaved each of the collagen samples 
with CNBr, and the resultant peptides were mapped in two 
dimensions and quantitated by digital imaging. A map from 
DHCB-treated cultures after 8 d of reexpression is presented 
in Fig. 5. It represents the midpoint of the phenotypic transi- 
tion of type II collagen, contains peptides from each of the 
collagen types, and provides an example of the calculations 
used  (see  Fig.  5,  legend)  to  obtain  the  time-course data 
presented in Figure 6. 
In this culture system enhanced synthesis of type III colla- 
gen is the major additive change that characterizes the RA- 
modulated  collagen  phenotype.  In  both  untreated  and 
DHCB-treated cultures type III synthesis dropped sharply 
(approximately eightfold)  during  the  first  two  days  after 
removal of RA (Fig. 6). DHCB-treated cultures maintained 
this  unstimulated  level  until  day  6  and  then  exhibited  a 
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Figure 3. Collagen synthesis during the reexpression period. Data 
are identified as in Fig. 2 and represent the average of  duplicate cul- 
tures. The mean of the ranges is  +11%. 
gradual decline. Untreated cultures showed a transient stim- 
ulation of type III synthesis on day 4 and then essentially fol- 
lowed the levels of synthesis in DHCB-treated cultures after 
day 6. The initial level of type I trimer synthesis was main- 
tained  by  DHCB-treated  cultures  until  day  8  and  then 
dropped more than fourfold by day 10.  In contrast, type I 
trimer  synthesis  in  untreated  cultures  abruptly  increased 
fourfold by day 2, declined to about the initial level by day 
6, and then remained at this level. Thus, once established by 
RA treatment in primary culture, type I trimer synthesis can 
be maintained in the absence of RA. Because the transient 
stimulation immediately followed the decline in type III syn- 
thesis, it may represent a rebound reutilization of the transla- 
tional apparatus. Regardless of  the cause, the stimulation was 
completely  blocked  by  DHCB-dependent  microfilament 
modification. Collectively these results define the first phase 
of reexpression, from day 0 to day 6, principally involved 
with the loss of stimulated, and subsequently RA-dependent, 
aspects of the RA-modulated collagen phenotype. 
The second phase of reexpression, after day 6, was defined 
by the reinitiation of differentiated characteristics originally 
suppressed by RA, namely type II collagen synthesis. Such 
synthesis  was  substantial  when  first  detected  in  DHCB- 
treated cultures on day 6 and maximal on day 14. The depen- 
dence of reexpression on microfilament modification was 
demonstrated by the fact that type II synthesis in DHCB- 
treated cultures was 8- and 10-fold greater than in untreated 
cultures at these times. DHCB treatment was also responsi- 
ble for the decline in type I-trimer synthesis which occurred 
after day 8, well after the reinitiation of type II synthesis. 
This and the late slow decline in type III synthesis were re- 
quired to establish the final collagen phenotype on day 14, 
which was essentially identical to that expressed by primary 
differentiated chondrocytes. The essential features of DHCB- 
dependent reexpression in this system have been replicated 
in three separate cell strains. These features include the de- 
cline in collagen types III and I trimer, the substantial return 
of type II collagen synthesis by 1 wk without cell rounding, 
and the final high proportion of type II collagen synthesis af- 
ter 14d. 
Serum Is Required for Reexpression 
In parallel experiments, RA-modulated secondary chondro- 
cytes were  tested  for DHCB-induced reexpression of the 
differentiated collagen phenotype in low serum concentra- 
tions (1 and 2%)or 10% serum. The collagen phenotype was 
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collagen phenotype using SDS-PAGE of 
collagen chains. Approximately equiva- 
lent amounts of radioactivity were load- 
ed in most lanes. (RA) Collagens from 
RA-modulated  cultures  labeled  in  the 
presence of RA at the beginning of the 
reexpression period. (C) Collagens from 
control secondary cultures never exposed 
to RA. The remaining lanes contain anal- 
yses from RA-modulated cells, cultured 
for various times  (indicated in days) in 
the absence of RA and the absence (-) 
or presence (+) of DHCB. (Arrowhead) 
Origin of the separating gel. Right inset 
allows visualization of the separation of 
ctl(I) and  al(l~  chains  and  contains  a 
lower fluorographic exposure of  the same 
8-d  +DHCB  sample  presented in  the 
time course region of the gel. 
Figure 5.  2-D CNBr peptide map of purified radioactive collagen 
from RA-modulated chondrocytes after 8 d of reexpression in the 
presence of DHCB and the absence of RA. Peptides from collagen 
types, I trimer, II, and HI are represented. The indicated peptides 
were quantitated by digital imaging in this map and maps from cul- 
tures treated with and without DHCB during the first 14 d of reex- 
pression described in Figs. 1-4. The percent distribution of  these col- 
lagens was determined from a single fluorographic exposure of each 
map with the intensity of each indicated peptide within the measur- 
able range of OD. These peptides were chosen because they were 
well resolved in all mixtures. The integrated OD for the indicated 
charge isomers of  al~-CB6 (small  arrowheads),  alflD-CB9,7 (/arge 
arrowhead), and al(m)-CB5 (medium arrowhead), were used to 
calculate total OD for these CNBr peptides by comparison with stan- 
dard maps. When the range of isomer intensities permitted, alternate 
isomers or the sum of  all isomers were used to verify the calculation; 
these values were within 10% of  those from the standard calculation. 
Quantitation of standard maps indicated that CB6 represented 24% 
of the total peptide OD of 0tl(I); CB9,7 represented 16.5% of ctl(II); 
and CB5 represented 32% of al0ID. OD of  each type of a-chain was 
summed, the percent distribution was calculated, and the synthesis 
per microgram DNA of  each collagen type was obtained by multiply- 
ing the decimal equivalent of these values by total collagen synthe- 
sized per microgram DNA. The resultant data are presented in Fig. 6. 
determined by 2-D CNBr peptide mapping (6, 8,  10) to pro- 
vide multiple peptide markers for the phenotypic transition 
to type II synthesis (Fig. 7). Cells labeled in RA at the begin- 
ning of the reexpression period contained no detectable type 
II collagen, as indicated by the absence of aI(II)CB10,5 and 
the other type II peptides (Fig. 7 a, arrowheads). Type III 
collagen peptides (brackets)  predominated over al(I) pep- 
tides (parentheses).  After 14 d in medium containing 1% se- 
rum, DHCB, and no RA, the phenotype was essentially un- 
changed except for traces of type II and  a2(I)  (Fig.  7  b). 
Similar results were obtained with 2 % serum (unpublished 
data).  In contrast,  when  10%  serum was used during  the 
reexpression period, type II collagen peptides were clearly 
dominant, al(I) peptides sharply reduced, type III peptides 
minimal, and ~t2(I)  peptides were essentially undetectable 
(Fig. 7 c). This pattern is the same as that for secondary con- 
trol chondrocytes at the beginning of the reexpression period 
(Fig. 7 d). These results verify the endpoint of reexpression 
described in Fig. 6 in a different cell strain and demonstrate 
the absolute requirement for serum during DHCB-induced 
reexpression. 
1~pe H Collagen lmmunofluorescence 
We determined the population of chondrocytes capable of 
producing type II collagen using a mAb specific for this col- 
lagen (25).  Approximately 70% of the chondrocytes in pri- 
mary  monolayer culture  for  14  d  exhibited  characteristic 
vesicular fluorescence (Fig. 8 a). In contrast, no intracellular 
fluorescence was detected in paired RA-modulated chondro- 
cytes after 10 d of treatment (Fig.  8 b).  However, traces of 
extracellular fluorescence were present, due to type II depo- 
sition before RA treatment.  Such uniformly negative cells 
were transferred to secondary culture in the presence of RA 
and released from RA exposure for 14 d in the absence (Fig. 
8 c) or presence (Fig.  8 d) of DHCB.  Only an occasional 
type II collagen-positive cell was detected in the absence of 
DHCB, whereas ,'050% of the cells were positive in its pres- 
ence. These results have been replicated in two separate cell 
strains and indicate that the changes in type II expression de- 
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Figure 6. Time course of reexpression  of the differentiated  pheno- 
type by RA-modulated  chondrocytes in secondary culture as mea- 
sured by changes in the synthesis of collagen types I trimer (trian- 
gles), II (circles), and III (squares).  Data were obtained  from the 
same cultures  described in Figs.  1-5. Reexpression  was in the ab- 
sence of RA and the presence (solid lines) or absence (dashed lines) 
of the  microfilament-modifying  drug,  DHCB.  The differentiated 
state  is characterized by high levels of type II synthesis  (circles). 
These data  were obtained  using  the calculations  described in the 
legend  to Fig.  5. 
tected biochemically result from the activity of many, but not 
all,  of the cells  in these cultures. 
Discussion 
We have previously shown that rabbit articular chondrocytes 
are  modulated  away  from  the  differentiated  phenotype  by 
subculture  (13)  and  induced  to reexpress  the  differentiated 
phenotype by the  transition  from a  spread  morphology in 
monolayer culture to a spherical morphology in agarose cul- 
ture (10).  This  shape-dependent  reversible  modulation sys- 
tem shares with mammary epithelia  (21),  synovial cells  (2, 
48),  and preadipocytes  (46)  the characteristic  that change 
away from a  flattened  morphology leads to both increased 
production and a  shift toward a  more differentiated pheno- 
Figure 7  Two-dimensional  CNBr peptide  maps of collage 
cultures  of RA-modulated  cells (a) labeled  at the beginnir 
reexpression  period in the presence of RA (10% +RA), (b) 
exposed to DHCB in 1% serum for 14 d (1% +DH), and (c) 
The Journal of Cell  Biology, Volume  106,  1988  166 Figure 8.  Type II collagen-specific immunofluorescence in chondrocytes after 14 d in primary culture (a and b) and after reexpression 
for 14 d in secondary culture in the absence of RA (c and d). Cells in (a) are controls; cells in (b) were treated with 1 Ixg/ml  RA between 
day 4 and 14 of primary culture. Reexpression (c and d) was in the absence (c) or the presence (d) of DHCB. Identical exposures and 
developing times were used in all cases. Bar, 20 gm. 
type. The positive response appears to be correlated with the 
in vivo expression of differentiated functions where the cell 
exhibits a three-dimensional morphology and may be mech- 
anistically related to the capacity of transformed cells to sur- 
vive in soft agar.  In contrast, anchorage-dependent spread 
cells, such as 3T3 and other fibroblast lines, respond to such 
exposed to DHCB in 10% serum for 14 d (10% +DH). The map 
from a paired control culture (never treated with RA) labeled at the 
beginning of reexpression is presented (d).  These  fluorographs 
were intentionally overexposed to enhance detection of minor pep- 
tides. Consequently, the proportion of any minor component ap- 
pears greater than it is in actuality. The quantitative assessment of 
properly exposed fluorographs in Fig. 6 more accurately reflects the 
composition of the reexpressed phenotype. The CNBr peptides of 
r  are indicated by arrowheads, oil(I) by parentheses, ctl(III) by 
brackets, and ct2(1) by asterisks. 
a change with a nearly universal suppression of  cellular func- 
tions (50). 
In the present report we have investigated the idea that 
transduction of shape information to the genome might be 
mediated by the organizational state of microfilament struc- 
tures, and more precisely, whether microfilament modifica- 
tion can signal phenotypic change without the involvement 
of alterations in cell shape (rounding). We have used DHCB 
as a specific perturbant of microfilament architecture (4, 14) 
because it does not alter glucose transport (4) and is well 
tolerated by chondrocytes and their modulated progeny (11). 
Both RA-modulated chondrocytes and subculture-modulated 
chondrocytes (where RA effects are not involved) respond to 
microfilament modification by DHCB with reexpression of 
the differentiated phenotype (7,  11). However, these results 
do not  necessarily implicate  microfilament signaling,  be- 
cause  a  previous  use  of DHCB  and  other  analogues  of 
cytochalasin B has been the stimulation of rounded or spheri- 
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duced  chondrogenesis  in  low-density chick  limb  mesen- 
chymal cells  (52).  Similarly, synovial fibroblasts  show  a 
positive  correlation between the  degree  of cell  rounding 
caused by different doses of cytochalasin B or other agents 
and the extent of collagenase induction (2). 
In the present experiments we have essentially eliminated 
cell rounding by using a low dose of DHCB (3  x  10  -6 M) 
and by using RA-modulated cells which are tightly adherent, 
possibly due to  increased  cellular binding  of fibronectin 
(22).  The employed dose is threefold less than required for 
initiation of rounding and ninefold less than required for 
complete arbofization of subculture-modulated chondrocytes 
(manuscript in preparation). In the present experimental sys- 
tem DHCB did not eliminate stress fibers but caused substan- 
tial modification of microfilament architecture (14). Thus, 
both microfilament-containing  and microfilament-free  mem- 
brane attachment plaques may still stabilize the spread mor- 
phology through interactions between the extracellular ma- 
trix (fibronectin [17, 45], chondronectin [23], collagen [47]) 
and linking proteins, such as fibronectin receptor complex 
(24, 27), collagen-binding proteins (34,  35), connectin (15), 
vinculin (17), and talin (27). 
In this environment of a stable spread morphology reex- 
pression proceeds in two phases. Chondrocytes first respond 
to  the  absence of RA.  This  results  in  the  rapid  DHCB- 
independent decline of type III synthesis, which was  en- 
hanced but not induced by RA treatment in primary culture 
(8). A compensatory coincident stimulation of type I trimer 
synthesis also transiently occurs in untreated cells. This is 
blocked in DHCB-treated cells, possibly as a result of the 
changes in microfilament architecture that occur at this time 
(14) and their potential effects on the translational apparatus 
(16, 28). These adjustments are complete by day 6. The sec- 
ond phase requires DHCB-dependent microfilament modifi- 
cation, consists of reexpression of the differentiated func- 
tions originally suppressed by RA, and partially overlaps the 
first phase.  Enhancement of proteoglycan synthesis is first 
detected on day 4 and precedes the reinitiation of type II syn- 
thesis that is detected on day 6. The early response of pro- 
teoglycan synthesis is consistent with its early suppression 
and greater sensitivity to RA in primary culture (8) and may 
reflect the operation of regulatory mechanisms that supple- 
ment or are different from those controlling the collagen 
phenotype. Essentially complete reexpression of the differ- 
entiated collagen phenotype occurs by day 14. Synthesis of 
type II collagen at this time is nearly identical to that of con- 
trol secondary chondrocytes. The transitions of  type II colla- 
gen and type I trimer are not coincident during this phase, 
because the suppression of type I-trimer synthesis only be- 
gins on day 10. Because of the absence of sensitive, specific 
antibodies to type I trimer, it has not been possible to deter- 
mine if the same cell synthesizes these two collagens, and 
whether such synthesis is simultaneous or temporally sepa- 
rated (previously shown for collagen types I and II [18, 19, 
49]). 
When reexpression in the presence of DHCB is essentially 
complete (14 d) the synthesis of type II collagen is restricted 
to ",,50% of the cells, based on type II collagen-specific im- 
munofluorescence.  These  cells  are  predominantly  well- 
spread and need not be involved in colony formation. In the 
absence of DHCB, little type II synthesis is detected bio- 
chemically. This is due to the presence  of an occasional 
producing cell rather than a low level of fluorescence in all 
of the larger population of cells capable of type II synthesis. 
The initial proportion of producing cells in primary mono- 
layer culture is slightly smaller than the 80%  reported for 
freshly isolated articular chondrocytes after overnight sus- 
pension culture (53). The difference may be due to the effects 
of monolayer  culture and may be enhanced by secondary cul- 
ture. It remains to be determined if  the proportion of produc- 
ing cells following reexpression in monolayer culture can be 
increased by transition to spherical shape in agarose culture. 
Although the synthetic history of a single cell cannot be de- 
termined by  intracellular immunofluorescence to  demon- 
strate phenotypic switching, it is important that the progeny 
of a single cloned chondrocyte cease producing type II colla- 
gen and begin producing type I and type I trimer (32). 
It is likely that reinitiation of type II collagen synthesis 
results predominantly from regulation at the level of tran- 
scription, although run-on transcription data are not avail- 
able. Pawlowski  et al. (38) have shown that suppression of 
type II synthesis in response to BrdU results from a parallel 
reduction of both nuclear and cytoplasmic type II procolla- 
gen mRNA. Finer et al. (18) demonstrated a reversible five- 
fold reduction in equilibrium levels of type II procollagen 
mRNA associated with the treatment and removal of PMA. 
Posttranscriptional events may also play a role, because they 
cause substantial changes in the synthesis of type I collagen 
(39) and other proteins (29).  However, in chondrocytes it is 
more likely that such events will influence the regulation of 
collagen type I and I trimer. Finer et al. (18) have demon- 
strated that the translational efficiency of type I procollagen 
mRNA is altered in PMA-treated chondrocytes and is 24-fold 
greater than that of type II procollagen mRNA after removal 
of PMA. In addition, partially processed (18) and untrans- 
lated mRNA for pro ctl(I) (1, 3) and pro ~t2(I) (20) have been 
detected in vertebral and virally transformed chondrocytes. 
It is not clear whether similar mechanisms account for the 
absence of ct2(I) synthesis during RA treatment of rabbit ar- 
ticular chondrocytes (8), when similar treatment of chicken 
sternal chondrocytes results  in the synthesis of heterotri- 
meric type I collagen (51). 
The transitions in synthesis of collagen types I, I trimer, 
and II are maximal within the time frame of 7-14 d after the 
initial stimulus for phenotypic change in the processes of 
modulation by RA (8),  subsequent DHCB-dependent reex- 
pression, and shape-dependent reexpression after modula- 
tion by subculture (10). In comparison with the rapid changes 
in type III synthesis stimulated by treatment (8) or removal 
of RA, and the early modifications in microfilament archi- 
tecture produced by DHCB (14), modulation of the differen- 
tiated collagen phenotype is delayed in onset and develops 
slowly.  This suggests the operation of complex regulatory 
mechanisms and/or slow changes in chromatin structure. 
The present results (and those in references 7 and 11) sug- 
gest that some change in microfilament organization can ini- 
tiate a signal that is capable of  altering the phenotype without 
mediation by events that only result  from cell  rounding. 
Similarly, Unemori and Werb (48) have shown in synovial 
fibroblasts that the transition to spherical  shape does not 
necessarily mimic the microfilament modifying effects  of 
cytochalasin B, which are capable of inducing collagenase 
production. Effective microfilament modification may alter 
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teins  to modulate  membrane-based  signaling.  This is sug- 
gested  by  the cytochalasin  D-dependent  reversal  of fibro- 
nectin-mediated  inhibition of chondrogenesis  (52)  and the 
assumed  membrane  origin of protein kinase  C-mediated, 
PMA-dependent  modulation of the chondrocyte phenotype 
(18).  The emphasis  on  microfilament modification during 
reexpression is not in conflict with the results of Horton and 
Hassel (26), which demonstrate  that RA can modulate spher- 
ical chondrocytes. A spread morphology is thus not a neces- 
sary  intermediate for RA-dependent change,  in contrast  to 
our initial expectations (8). With regard to reexpression, the 
present study  suggests that an important  aspect of the RA- 
signaling mechanism is stabilized by monolayer culture  so 
that simple removal of RA does not result  in reexpression. 
Reexpression  also  exhibits  an  absolute  requirement  for 
10% FCS. The concentration of factor(s)  in 1 or 2% serum 
is not sufficient to permit reexpression even though DHCB- 
dependent modification of microfilaments is essentially iden- 
tical in both  10 and 2 % serum (14). The mechanism of this 
synergism is not presently known but similar effects are seen 
during chondrogenesis  (41).  Limb mesenchyme requires a 
prior  commitment  step  before cytochalasin  D  can  induce 
chondrogenesis (52). This process has been clarified by stud- 
ies  with purified  cartilage-inducing  factor A/transforming 
growth  factor  13  (41,  44).  Rat  muscle  mesenchymal  cells 
can be committed to chondrogenesis by this factor alone but 
do  not  express  the  phenotype  until  stimulated  by  shape- 
change or microfilament modification with DHCB. The use 
of multiple  factors  may  bypass  the  requirement  for overt 
shape change (30).  It is not yet clear whether cartilage-in- 
ducing factor A and the factor required for reexpression are 
identical. 
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